Amphenol vs Roche: Founders, CEOs and History
Amphenol was founded in 1932 by Arthur J. Schmitt and is led by R. Adam Norwitt. Roche was founded in 1896 by Fritz Hoffmann-La Roche and is led by Thomas Schinecker.
Company facts
Founders
Amphenol
Arthur J. Schmitt
Amphenol was founded in Chicago in 1932 by an effective, pragmatic entrepreneur named Arthur J. Schmitt.
Roche
Fritz Hoffmann-La Roche
Fritz Hoffmann-La Roche (1868-1920) founded F. Hoffmann-La Roche & Co. in Basel on 1 October 1896, at age 28.
CEOs and their tenures
Amphenol
- Arthur J. Schmitt1932–1964
Founder and Chief Executive Officer
Arthur J. Schmitt founded American Phenolic Corporation in Chicago in 1932 and led it as chief executive until 1964.
Source - Martin H. Loeffler1996–2008
Former Chief Executive Officer and Chairman
Martin H. Loeffler was Amphenol's chief executive from 1996 to 2008, president from 1987 to 2006 and chairman of the board from 1997 until he retired from the board at the May 2026 annual meeting.
Source - R. Adam Norwitt2009–present
Chairman, President and Chief Executive Officer
R. Adam Norwitt has been Amphenol's chief executive since January 1, 2009 and added the role of chairman of the board in 2026. Net sales grew from $2.82 billion in 2009 to $23.09 billion in fiscal 2025 and the GAAP operating margin reached a record 25.4%.
Source
Roche
- Severin Schwan2008–2023
Chief Executive Officer
Serving as CEO from 2008 to 2023, he cemented Roche's absolute dominance in global oncology and highly advanced diagnostics before moving to Chairman of the Board.
Source - Thomas Schinecker2023–present
Chief Executive Officer
Under Schinecker, Roche returned to growth after the COVID testing decline: 2025 sales rose 7% at constant rates to ~$73.8 billion (CHF 61.5 billion) and 12 late-stage studies read out positively that year.
Source
Timeline: Amphenol and Roche side by side
1896Roche
F. Hoffmann-La Roche Founded in Basel
Fritz Hoffmann-La Roche founds the enterprise in Basel, Switzerland, pioneering mass-manufactured, chemically standardized prescription pharmaceuticals.
1898Roche
Commercial Breakthrough with Sirolin
Roche launches non-prescription cough syrup Sirolin, achieving widespread international distribution and financing early clinical laboratories.
1932Amphenol
Arthur J. Schmitt founds American Phenolic Corporation
Arthur J. Schmitt incorporates American Phenolic Corporation in Chicago with a patented molded phenolic radio tube socket, establishing the company's foundation in electronic component manufacturing.
1934Roche
First Industrial Synthesis of Vitamin C
Roche becomes the first company to mass-produce synthetic Vitamin C (Redoxon) at industrial scale, anchoring decades of high-margin global cash flow.
1936Amphenol
Introduction of industry-standard 75 series microphone connector and lock-in socket
Amphenol introduces the 75 series uniform microphone connector and a lock-in socket for radio tubes, both becoming industry standards and attracting RCA as a major customer ordering 10,000 sockets daily.
1942Amphenol
Primary supplier of AN connectors for WWII Allied forces
Amphenol becomes a critical defense supplier, with its 5015 AN circular connectors becoming standard equipment on military aircraft and communications gear; A-N connector shipments increase 13,572% from January 1941 to March 1943.
1942Amphenol
Official name change to Amphenol Electronics Corporation
The company officially changes its name from American Phenolic Corporation to Amphenol Electronics Corporation, formalizing the shorthand name customers had used for years.
1945Amphenol
Initial public offering
Amphenol raises $1.5 million from convertible debentures and sells 345,000 shares at $10 per share, giving the company a $4 million market capitalization and providing capital for post-war diversification.
1951Amphenol
Amphenol engineers develop the BNC connector
Amphenol engineers Paul Neill and Carl Concelman develop the bayonet coupled BNC coaxial connector, which becomes a standard interface in radio frequency and test equipment applications.
1957Amphenol
NYSE listing
Amphenol Electronics Corporation lists on the New York Stock Exchange, marking its transition to a major public industrial company.
1958Amphenol
Merger with George W. Borg Corporation
Amphenol completes its largest transaction to date, merging with the George W. Borg Corporation, a maker of automobile clocks, electronic instruments and deep pile fabrics, and is renamed Amphenol-Borg Electronics Corporation.
1963Roche
Launch of Valium (Diazepam)
Roche introduces Valium, which becomes the world's most widely prescribed psychotropic medication and establishes global pharmaceutical leadership.
1967Amphenol
Acquisition by Bunker-Ramo Corporation
Bunker-Ramo Corporation acquires Amphenol, which begins operating as a subsidiary and passes through successive corporate owners for the next 24 years.
1968Roche
Establishment of Roche Diagnostics
Roche launches its dedicated diagnostic division, laying the foundation to become the world's preeminent in-vitro diagnostics (IVD) provider.
1981Amphenol
Allied Corporation buys Bunker-Ramo for $358 million
Allied Corporation acquires Bunker-Ramo for $358 million, including the Amphenol division, making Amphenol part of a larger industrial conglomerate.
1987Amphenol
LPL Investment leveraged buyout for $430 million
LPL Investment buys Amphenol from Allied in a leveraged buyout valued at $430 million in cash, and the decentralized management style that defines the modern company takes hold. Martin H. Loeffler becomes president in the same year.
1991Amphenol
Second IPO on NYSE under ticker APH
Amphenol returns to public markets with a second initial public offering on the New York Stock Exchange under ticker APH, beginning the modern era of sustained growth and shareholder returns.
2005Amphenol
Acquisition of Teradyne connector business for $390 million
Amphenol acquires Teradyne's connection systems business for $390 million in October 2005, expanding its presence in high speed data and backplane connectors for the growing IT datacom market.
2008Roche
Severin Schwan becomes CEO
Severin Schwan became CEO of F. Hoffmann-La Roche in 2008. Led Roche for 14 years; handed over to Thomas Schinecker in March 2023 and became chairman.
2009Roche
Full Acquisition of Genentech for $46.8 Billion
Roche completes its historic $46.8 billion buyout of American biotechnology pioneer Genentech, securing market leadership in oncology biologics.
2016Amphenol
Acquisition of FCI Asia for $1.275 billion
Amphenol acquires FCI Asia from affiliates of Bain Capital for $1.275 billion in January 2016, strengthening its global connector footprint and adding high speed backplane and board-to-board capability.
2018Roche
Foundation Medicine & Flatiron Health Acquisitions
Roche acquires Foundation Medicine and Flatiron Health, integrating real-world oncology data analytics and genomic profiling into personalized healthcare.
2021Amphenol
Acquisition of MTS Systems Corporation for $1.7 billion
Amphenol acquires MTS Systems for $1.7 billion in April 2021, adding advanced sensor capability that deepens its position in industrial and automotive sensing.
2023Roche
Acquired Telavant
F. Hoffmann-La Roche acquired Telavant for $7.1 billion. Roche paid $7.1 billion upfront for Telavant to gain US and Japan rights to the anti-TL1A antibody RVT-3101 (afimkibart) for inflammatory bowel disease.
2024Amphenol
Acquisition of Carlisle Interconnect Technologies for about $2.0 billion
Amphenol completes the purchase of Carlisle Interconnect Technologies from Carlisle Companies in May 2024 for about $2.0 billion, expanding aerospace, defense and medical harsh environment interconnect capability.
2025Amphenol
Completion of the $2.1 billion CommScope outdoor wireless and DAS purchase
Amphenol completes the acquisition of CommScope's Outdoor Wireless Networks and Distributed Antenna Systems businesses, including Andrew, for $2.1 billion in cash. The businesses had about $1.2 billion of 2024 sales.
2025Amphenol
Record fiscal 2025 revenue of $23.09 billion, up 52%
Amphenol reports record full year 2025 net sales of $23.09 billion, up 52% year over year and 38% organically, with a 25.4% GAAP operating margin, $4.4 billion of free cash flow and Communications Solutions sales up 91% to about $12.1 billion.
2025Roche
Group Sales Reach CHF 61.5 Billion
Under CEO Thomas Schinecker, Roche delivers group sales of ~$73.8 billion (CHF 61.5 billion), driven by ~$57.2B (CHF 47.7B) in Pharmaceuticals and ~$16.6B (CHF 13.8B) in Diagnostics.
2026Amphenol
Completion of the $10.5 billion CommScope CCS acquisition
Amphenol closes its largest acquisition, buying CommScope's Connectivity and Cable Solutions business for $10.5 billion on January 12, 2026. Amphenol also acquired the CommScope name and expects the business to generate about $4.1 billion of sales in 2026.
2026Amphenol
Norwitt named chairman as Loeffler retires from the board
Amphenol announces on February 4, 2026 that chief executive R. Adam Norwitt will also become chairman of the board at the May 2026 annual meeting, as Martin H. Loeffler retires from the board after more than five decades with the company.
Acquisitions
Amphenol
- CommScope Connectivity and Cable Solutions (CCS)2026$10.5B
- CommScope Outdoor Wireless Networks and Distributed Antenna Systems businesses (Andrew)2025$2.1B
- Rochester Sensors2025Undisclosed
- Trexon2025$1B
- Carlisle Interconnect Technologies (CIT)2024$2B
Roche
- PathAI2026$1.1B
- 89bio2025$3.5B
- Telavant2023$7.1B
- Carmot Therapeutics2023$2.7B
- Foundation Medicine2018$2.4B
- ForSight VISION42017Undisclosed
Questions about Amphenol vs Roche
Who is the CEO of Amphenol Corporation and F. Hoffmann-La Roche AG?
Amphenol Corporation is led by R. Adam Norwitt and F. Hoffmann-La Roche AG is led by Thomas Schinecker. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Amphenol Corporation founded vs F. Hoffmann-La Roche AG?
F. Hoffmann-La Roche AG was founded in 1896 — 36 years before Amphenol Corporation, which was founded in 1932. F. Hoffmann-La Roche AG's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Amphenol Corporation.
How many employees does Amphenol Corporation have compared to F. Hoffmann-La Roche AG?
Amphenol Corporation employs approximately 170,000 people, while F. Hoffmann-La Roche AG employs approximately 112,774. Amphenol Corporation has the larger workforce at 170,000 employees, compared to F. Hoffmann-La Roche AG's 112,774. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Amphenol Corporation and F. Hoffmann-La Roche AG headquartered?
Amphenol Corporation is headquartered in United States and F. Hoffmann-La Roche AG is headquartered in Switzerland. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded Amphenol Corporation and F. Hoffmann-La Roche AG?
Amphenol Corporation was founded by Arthur J. Schmitt. F. Hoffmann-La Roche AG was founded by Fritz Hoffmann-La Roche.
Which company has a longer operating history — Amphenol Corporation or F. Hoffmann-La Roche AG?
F. Hoffmann-La Roche AG has been operating for approximately 130 years, making it the more established of the two companies. Amphenol Corporation has been in operation for around 94 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Amphenol vs Roche overview